Drug Trial Radar · NCT07872306
A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Dec 15, 2026
Primary completion
Dec 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Satellos Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD
Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
forazapadinDrug
Forazapadin (SAT 3247) is a potent, orally available, muscle penetrant, small molecule inhibitor of AAK1
Placebo ComparatorDrug
Matching placebo oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation of forazapadin in FSHDTime frame: 48 weeks
- Efficacy of forazapadin as treatment in FSDHTime frame: 24 and 48 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.